Clinical Trial Search

Primary: SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort — 15; 3; 16; 18 Participants

Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…

Primary: Participants Enrolled — 36 Participants

Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants

Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…

Primary: Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection — 12.2; 31.8; 89.6 events per 100 person years

Primary: Number of Participants With Each Score on WHO 7-point Outcome Scale at Day 7 — 6; 0; 20; 8 Participants — p=0.0346

Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants

Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants

Primary: Antibody Concentrations in Maternal Blood in Pregnant Women in England — 37.2; 7.2; 80.3; 590.5 CAU/ml

Primary: Change of Arterial Oxygenation at 48 Hours From Enrollment — 200; 183 ratio

Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg

Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…

Primary: Number of Participants With SARS-CoV-2 IgG Antibodies — 14 Participants

Primary: Improvement in Oxygenation — 25.7; 29.7 ratio

Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant

Primary: Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7 — -2.04; -1.51; -1.24…

Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events

Primary: Positive Percent Agreement — 52 percent of nasal swabs

Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…

Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants

Primary: Mechanical Ventilation — 1; 1 Participants

Primary: Number of Serious Adverse Events Relative to Treatment Group — 1; 3; 0 participants

Primary: Dental Health Care Worker (DHCW) Willingness to Participate in the Study — 10 Participants

Primary: Number of Subjects That Are Alive Without Respiratory Failure at Day 29. — 17; 14 Participants

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants

Primary: Number of Participants With Worsening of COVID-19 Within 28 Days — 1; 1 Participants

Primary: Rate of Perinatal Transmission of SARS-CoV-2 — 12.3 percentage of participants

Primary: SARS-CoV-2 Infection — 4; 2 Participants